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Summary 
The La/SSB autoantigen is a major target of long-term humoral autoimmunity in 
primary Sjögren’s Syndrome (SS) and systemic lupus erythematosis.  A majority of 
patients with linked anti-Ro60/Ro52/La responses target an NH2-terminal 
epitope designated LaA that is expressed on Ro/La ribonucleoprotein complexes 
and the surface membrane of apoptotic cells.  In this study, we used high 
resolution Orbitrap mass spectrometry to determine the clonality, isotype and V-
region sequences of LaA-specific autoantibodies in 7 patients with primary SS.  
Anti-LaA IgGs purified from polyclonal sera by epitope-specific affinity 
chromatography were analysed by combined database and de novo mass 
spectrometric sequencing.  Autoantibody responses comprised two heavily 
mutated IgG1 kappa-restricted monoclonal species that were shared (public) 
across unrelated patients; one clonotype was specified by an IGHV3-30 heavy 
chain paired with IGKV3-15 light chain and the second by an IGHV3-43/IGKV3-20 
pairing.  Shared amino acid replacement mutations were also seen within heavy 
and light chain complementarity-determining regions, consistent with a common 
breach of B cell tolerance followed by antigen-driven clonal selection.  The 
discovery of public clonotypic autoantibodies directed against an 
immunodominant epitope on La, taken together with recent findings for the linked 
Ro52 and Ro60 autoantigens, supports a model of systemic autoimmunity in which 
humoral responses against protein-RNA complexes are mediated by public sets of 
autoreactive B cell clonotypes. 
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Introduction  
High-titer IgG autoantibodies to the 48 kDa La/SSB protein are a serological 
hallmark of primary Sjögren’s syndrome (SS) but also associated with systemic 
lupus erythematosis (SLE) and the neonatal lupus syndrome1-3.  La is physically 
linked with 60 kDa Ro/SSA (Ro60) protein in ribonucleoprotein (RNP) complexes 
comprising small noncoding cytoplasmic (Y) RNAs termed hYRNAs4 that are 
thought to drive combined anti-Ro60/La humoral responses via T cell-dependent 
intermolecular determinant spreading5.  Autoantibodies to a structurally unrelated 
52 kDa Ro/SSA protein (Ro52) (also termed TRIM21) are invariably part of these 
linked sets but can also occur as an isolated species6.  The physiological role of La 
is to serve as a termination factor for RNA polymerase III7 and to stabilize single 
stranded DNA during DNA metabolism8.  Epitope mapping of the La autoantigen in 
patients with primary SS has revealed three immunodominant regions: LaA 
(amino acids (aa)1-107); LaC (aa111-242); and LaL2/3 (aa346-408)9.  
Autoantibodies directed against the conserved winged-helix LaA determinant10 are 
of particular significance because they occur in ~100% of precipitin-positive sera 
and appear to arise early in the anti-La response9,11; are present at the highest 
concentration (mg/ml range) of any determinant12; bind the analagous LaA 
apotope on the surface of apoptotic cells where they form IgG-immune 
complexes13-14; react with a conserved discontinuous epitope15; and are present in 
sera from ~80% of mothers of children with congenital heart block14.  
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While an early study reported restricted heterogeneity and kappa light chain 
oligoclonality of humoral responses against recombinant fragments encompassing 
LaC and LaL2/316, nothing is known at a molecular level about the variable (V) 
gene usage and V region mutational status of spontaneous human anti-La 
autoantibodies in patients with primary SS and degree of sharing of V region 
structures among anti-Ro52/Ro60/La responses.  We have recently developed a 
proteomic method that allows near full- length protein sequencing of epitope-
specific populations of autoantibodies purified from whole serum17-19.  This 
approach utilizes high-resolution Orbitrap mass spectrometry (MS) and differs 
from traditional single cell approaches by determining the molecular signature of 
the secreted autoantibody proteome.  Our initial studies have showed that the 
response against an immunodominant determinant on Ro60, termed Ro60peg, is 
monoclonal, IgG1 kappa-restricted and specified by a characteristic HV3-23 heavy 
chain and KV3-20 light chain pairing that is shared (public) among unrelated 
patients17.  Likewise, responses to Ro52/TRIM21 are restricted to two public IgG1 
kappa clonotypes comprising a HV3-7 or HV3-23 encoded heavy chain paired with 
a KV3-20 light chain18.  Direct autoantibody sequencing has also revealed common 
and random somatic mutations in the heavy and light chain complementarity-
determining regions (CDRs) of these autoantibodies, consistent with antigen-
driven clonal selection.  The aim of the current study was to determine whether 
humoral responses to the immunodominant LaA epitope comprise similar sets of 
public clonotypes and whether these share molecular signatures with anti-
Ro52/60 autoantibody-specific proteomes.  Accordingly, we have characterized 
serum Ig proteomes selected on LaA protein in patients with primary SS using MS 
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and identified additional patterns of public clonotypes linking humoral anti-Ro/La 
autoimmunity. 
Materials and Methods 
Patients and controls 
Sera were collected from 7 primary SS patients with anti-Ro/La autoantibodies 
who were positive for anti LaA on a glutathione-S-transferase (GST)-LaA fusion 
protein enzyme-linked immunosorbent assay (ELISA).  The relative affinities of 
autoantibodies directed against the LaA, LaC and LaL2/3 epitopes determined by 
the KCSN elution method12 are included in table S1.  Patient characteristics and 
serological findings are presented in table 1.  Controls included 2 anti Ro/La 
positive primary SS patients who were anti-LaA negative, 1 asymptomatic donor 
with anti-Ro/La with anti-LaA and 4 healthy donors.  Patients with primary SS 
fulfilled at least 4 of the 6 American-European Consensus Group Criteria20.  None 
of the patients had evidence of malignant B cell disorders nor were being treated 
with steroids or other immunosuppressive drugs.  The study was approved by the 
Southern Adelaide Human Research Ethics Committee. 
 
Preparation of affinity purified anti-LaA autoantibodies 
CNBr-activated Sepharose 4B beads (Pharmacia, Sweden) were coupled with the 
soluble recombinant GST-LaA fragment (aa 1-107) according to the manufacturer’s 
recommendations.  Five milliliters of serum from each patient or control subject 
was passed over the column and washed overnight with phosphate buffered saline 
(PBS, pH 7.4).  The bound IgG fraction was eluted with 0.1M glycine in 0.5M NaCl, 
pH 2.3 and neutralized in 1M Tris HCl, pH 8.0.  The resulting fraction was dialyzed 
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against PBS overnight at 4 degrees and then concentrated in an Amicon-Ultra 15 
centrifugal filter (Millipore, MA, USA) to a final volume of ~500μL. 
 
Analysis of specificity of affinity purified anti-LaA by ELISA 
The activity and specificity of affinity purified IgGs were determined by testing the 
starting serum (1:500 dilution), flow through fraction (volume normalized to the 
starting serum) and the eluted bound fraction (1:50 dilution) on two ELISA sets.  
The first tested the specificity of the affinity purified IgG on various recombinant 
La fragments and native La.  The various La fragments were expressed as GST 
fusion protein constructs prepared from the pGEX vector (New England BioLabs, 
MA, USA). The plates (Maxisorp; Nunc, Denmark) were coated with 5μg/mL of 
native La (Arotec Diagnostics, New Zealand), GST-LaA, GST-LaC (aa111-242), and 
GST control in 0.03M carbonate buffer (pH 8.2).  Non-specific sites were blocked 
with 3% skim milk powder and duplicate wells were incubated with the different 
fractions.  Bound IgG was detected with anti-human IgG conjugated with alkaline 
phosphatase as described previously21.  The second ELISA set tested the affinity-
purified anti-LaA sample against native Ro60 (Arotec Diagnostics), full length 
Ro52 expressed in a maltose binding protein (MBP) fusion construct from the 
pMAL vector (New England Biolabs) and MBP control.  
 
Two-dimensional gel electrophoresis (2-DE) 
Affinity-purified anti-LaA samples were precipitated using a 2-D Clean Up Kit 
according to the manufacturers recommendations (BioRad, CA, USA) and were 
analysed using 2-DE as described17.   
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Mass spectrometry (MS) 
Samples were prepared for MS from either in-solution digests of affinity-purified 
IgGs or from heavy and light chain or intact immunoglobulin plugs excised from 2-
DE gels as described18.  Analysis of peptides was carried out in a Thermo Orbitrap 
XL linear ion trap mass spectrometer fitted with a nanospray source (Thermo 
Scientific, MA, USA) as detailed previously18. 
 
Protein sequence data analysis 
Database searches were first carried out with Proteome Discoverer version 1.2 
(Thermo Scientific) using the Sequest algorithm against two combined databases; 
the ImMunoGeneTics (IMGT) (http://www.imgt.org) and the Uniprot 2010-06 
databases.  The database search parameters were as follows: a maximum of 2 
missed trypsin cleavages; cross-correlation scores (Xcorr) matches of >1.5, 2.0, 
2.25, 2.5 and 2.75 for charge states of 1, 2, 3, 4 and 5, respectively; high peptide 
probabilities; and 2 or more unique peptides sequenced for each protein.  The 
mass tolerance for peptide identification was 10ppm for precursor ions and 0.01 
Da for product ions.  Searches were carried out with the following modifications: 
the oxidation of methionine; phosphorylation of serine, threonine and tyrosine; 
and carboxymethylation of cysteine.  
 
De novo sequencing and mutational analysis of purified IgGs 
De novo sequencing was performed on raw data files with Peaks Studio version 5.3 
(Bioinformatics Solutions, ON, Canada).  As there is a large degree of sequence 
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homology between the various Ig gene families the following strict set of rules 
were followed to minimize erroneous assignments of families: all spectra were 
manually inspected for quality; peptide lists were generated from the Peaks 
software program; a minimum of two framework (FR) peptides were matched 
back to the germline sequence; and sequence homology had to be >80% when the 
sequences were Ig Blasted (http://www.ncbi.nlm.nih.gov/projects/igblast) against 
the IMGT database.  Further data refinement parameters were set in the Peaks 
software program; scans were merged with a retention time of 1 minute, a 
precursor m/z error tolerance of 10ppm and a minimum charge state of 2.  Scans 
were filtered for a precursor mass of between 350 and 5,000 Da and a quality 
value of >0.65.  Mutational analysis and deviations from the germline IMGT 
sequence were carried out using the SPIDER search tool by searching against the 
combined IMGT/Uniprot 2010-06 databases with the following parameters: a 
homology match query type; a mass error tolerance of 0.01Da; and the previously 
described variable modifications18. 
 
Results 
Isolation of monospecific anti-LaA IgG from polyclonal anti-Ro/La sera 
Previously, we have developed a proteomic approach to analyze self-reactive anti-
Ro52/Ro60 clonotypes present in human polyclonal sera17-18.  The first step 
involves affinity selection of autoantibodies specific for either an 
immunodominant determinant or the intact autoantigen, in this case the clinically 
important LaA epitope located at the NH2-terminus of La protein (Fig. 1a).  
Accordingly, anti-Ro/La-positive sera from 7 subjects with primary SS were passed 
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over individual GST-LaA columns followed by extensive washing, and eluted IgGs 
confirmed as specific for LaA by analyzing starting serum, flow through and eluted 
fractions on Ro52/Ro60/La ELISAs (Fig. 1b,c).   In control experiments, no eluted 
IgG was detected after normal human sera (n = 4) or sera from primary SS patients 
without anti-LaA (n=2) were passed over the GST-LaA column.  Furthermore, no 
IgGs were detected in column eluates after anti-LaA-positive sera (n=3) were 
passed over a sham GST column. 
 
The anti-LaA autoantibody population is biclonal and comprises unique 
heavy/light chain pairings    
The clonality of the affinity-purified anti-LaA samples was then assessed using 
high-resolution 2-DE.  Under reduced conditions anti-LaA IgG resolved into several 
overlapping heavy chain species migrating at 55kD with a range of isoelectric 
points (pI) from 7 to 8.5 (Fig.2a).  These spots likely represent charge variants due 
to posttranslational modifications of oligoclonal species such as glycosylation, as 
has been observed previously for mouse monoclonal antibodies and a clonotypic 
anti-Ro60 autoantibody17,22-23.  Light chains, evident at ~25kD, resolved into 4 
equally spaced spots ranging in pI from 5.2 to 6.8, identified as IGKV3-15 (gel plugs 
2 and 3) and IGKV3-20 (gel plugs 3 and 4) (Fig.2a).  The complete heavy chain area 
was gel excised and found to comprise two dominant V gene families, IGHV3-43 
and IGHV3-30.  In order to determine actual heavy and light chain pairing, non-
reduced 2-DE gels of anti-LaA IgG were performed and revealed biclonal species of 
similar staining intensity migrating to 150kD, one comprising a IGHV3-30/IGKV3-
Archived at the Flinders Academic Commons: http://dspace.flinders.edu.au/dspace/ 
 11 
15 pairing and the second a IGHV3-43/IGKV3-20 pairing as identified by MS 
(Fig.2b).  
 
De novo MS sequencing of LaA-specific clonotypic autoantibodies 
In order to confirm both the clonality and heavy and light chain pairings of anti-
LaA IgGs as detected on gel plug digests, and determine the extent of IgV-region 
somatic hypermutation , we performed in-solution trypsin digests of purified anti-
LaA IgGs followed by combined database and de novo Orbitrap MS sequencing as 
described17-18.  This confirmed the presence of the two IgG1 heavy chain species, 
IGHV3-30 and IGHV3-43, and two kappa light chains encoded by IGKV3-20 and 
IGKV3-15.  JK2 and JK4 regions were identified from in-solution digests together 
with a single heavy chain JH2, indicating that the IGHV3-43 and IGHV3-30 
clonotypes utilize a single J-region.  Extensive aa replacement mutations within the 
V- and J- regions were identified using the Spider analysis module (Peaks 
software) in the anti-LaA samples from the 7 patients with primary SS (supporting 
information, Fig. S1a-e).  Public (common) mutations that are shared among 
patients are tabulated by proteomic heat maps shown in Fig. 3.  These are present 
in both FR and CDRs of each clonotypes; notably, a serine to asparagine 
substitution at aa31 in the CDR1 region of the IGKV3-20-encoded light chain was 
present in all 7 primary SS patients, as was an arginine to lysine at aa16 in the FR1 
region of the IGHV3-30-encoded heavy chain.  
 
Discussion 
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In this study, we have determined the secreted autoantibody proteome specific for 
an epitope on La protein that is expressed as an apotope on the surface of 
apoptotic cells and available for binding of maternal anti-La in congenital heart 
block.  A combination of affinity purification, isoelectric focusing and de novo MS 
sequencing identified two dominant public IgG1 kappa clonotypes in unrelated 
patients with primary SS: one specified by a heavy chain derived from the HV3-30 
gene segment paired with a KV3-15 light chain; and the second comprising a HV3-
43/KV3-20 pairing.   These findings extend recent proteomic analyses of anti-Ro60 
and anti-Ro52 autoantibodies that show similar properties of clonal restriction 
and expression of public clonotypes17-18.  The MS approach used herein can 
identify fine clonotypic specificities undetectable by routine immunoassays, and 
has a key advantage over human hybridoma and recombinant antibody single-cell 
methods in that it represents the global autoantibody repertoire against a 
structurally defined determinant19.  Furthermore, the proteomic approach can 
readily detect expressed public clonotypes in unrelated patients without selection 
bias and use their molecular signatures in a targeted MS diagnostic platform18.   
Combined data from the anti-Ro52/Ro60/La autoantibody proteomes tested thus 
far support a model of autoantibody production against linked protein-RNA 
complexes in systemic autoimmunity that is based on the utilization of a 
remarkably restricted set of autoreactive public B cell clonotypes, and challenge 
the general view that these responses are highly diversified, heterogeneous and 
polyclonal in outbred populations.   The origin of these disease-specific, interlinked 
public clonotypes, that we consider hallmarks of long-term humoral 
autoimmunity, remains unknown.  An implied corollary is that patients expressing 
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public Ro/La-specific clonotypes share common pathways of autoimmunity to 
multiple determinants on Ro/La complexes.  In brief, we propose that intrinsic 
defects in early B cell tolerance checkpoints in patients predisposed to Ro/La 
autoimmunity24 may allow the emergence of low affinity germline-encoded 
clonotypes that preferentially use certain heavy and light chain pairings; these may 
be exposed in secondary lymphoid organs to Ro52/Ro60/La determinants on 
poorly cleared apoptotic and/or necrotic remnants and undergo clonal selection, 
expansion and affinity maturation in dysregulated germinal centres25.  The role of 
clonal selection in the generation of these clonotypes is supported by the presence 
of shared and random aa replacement mutations in the CDRs of the LaA-specific 
clonotypic IgGs, notably those from serine to arginine or asparagine that are 
known to produce changes in binding affinity26.  Autoreactive memory B cells 
arising from primary immune responses in germinal centers may conceivably 
migrate to inflamed salivary glands in patients with primary SS where they may 
reside for months or years before expansion to clones of plasma cells during recall 
responses, thereby maintaining long-lived humoral Ro/La autoimmunity.  
Interestingly, plasma cells specific for Ro52, Ro60 and La have been identified 
earlier in salivary glands from patients with seropositive primary SS, but their IgV 
region signatures have yet to be determined27.   
 
A key finding now emerging from the sequencing of Ro/La autoantibody 
proteomes is the shared expression of Ig light and heavy chain V and J gene 
segments across these responses.  For example, anti-Ro52 proteomes have the 
same HV3-23/KV3-20 pairing signature as the anti-Ro60peg clonotype, and KV3-
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20 is shared by clonotypes that encompass the entire Ro52/Ro60/La response, 
with KV3-20 combined with KJ2 for anti-LaA/Ro60peg clonotypes17-18.  In addition 
to the sharing of germline-encoded structures, which suggests a role for 
recombinatorial bias in the generation of these linked, autoreactive species, 
clonotypes are specified further by shared somatic mutations consistent with the 
notion that they are generated through independent antigen-driven clonal 
selection events.  It is also conceivable that presentation of clonotypic V-region 
determinants on MHC class II by Ro- or La-specific B cells to cognate idiotypic-
specific T helper cells may in part drive determinant spreading in Ro/La humoral 
autoimmunity28-30.  This receptor presentation model of autoantibody 
diversification provides an alternative to an intermolecular T-B cell help model 
based on MHC class II presentation of antigenic Ro or La peptide determinants to 
cognate T cells5.  Further proteomic studies on other La epitope-selected 
autoantibodies will help determine whether intramolecular responses beyond LaA, 
in particular high affinity autoantibodies against the central LaC epitope, share 
public clonotypes.  It will also be important to examine whether the findings for 
Ro/La are generalisable to other linked sets of human autoantibodies.   
 
The affinity enrichment and MS sequencing protocol detailed herein can be used to 
determine IgV-region molecular signatures of secreted autoantibodies present in 
complex serum mixtures.  In conjunction with a targeted mass spectrometry 
diagnostic platform that utilises Ig proteome-derived V-region surrogate peptides, 
it potentially represents a major advance over routine immunoassays that have 
dominated autoimmune serology for decades.  One limitation is that the 
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methodology does not always obtain full sequence through the diversity (D) 
region18, compounded by the marked DH segment variability of autoantibodies 
from patients with SLE31.  Priority should be given to isolate autoantigen-specific 
cells from blood or inflamed salivary glands, using labeled Ro/La determinants or 
single-cell recombinant antibody techniques, potentially in combination with PCR 
based methods to target specific gene families utilized by secreted Ro/La-specific 
clonotypes.  Recently published refinements of the methodology have compared 
mass spectra data derived from mass spectrometry-based sequencing to reference 
V-region databases derived from next-generation sequencing of B cell 
repertoires32-34.  Finally, it may be feasible to identify specific clonotypes in whole 
cell proteomes of patient memory B cells and/or plasma cells by targeted mass 
spectrometry (which can detect a peptide in a complex sample at pg/ml 
sensitivity), using mutated V-region surrogate peptides derived from serum anti-
Ro/La clonotypes. 
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                                            Figure legends 
Fig. 1.  Specificity of anti-LaA IgGs purified by LaA epitope-specific affinity 
chromatography from sera of patients with primary SS containing anti-
Ro52/Ro60/La autoantibodies. (a) Immunodominant  epitopes on La are mapped 
as LaA (aa 1-107), LaC (aa 111-242) and LaL2/3 (aa 346-408). LaA is an NH2-
terminal conformation epitope requiring two regions of the protein to come 
together (filled areas) for immunoreactivity. (b) Purified IgGs tested by enzyme-
linked immunosorbent assay (ELISA) for specificity to intact La using native La, 
native Ro60, maltose binding protein (MBP)-Ro52 and MBP control. The starting, 
flow-through and eluted (affinity purified) fractions are compared. (c) Fine 
specificity of purified IgGs determined by ELISA using recombinant glutathione-s-
transferase (GST)-full-length La, GST-LaA and GST-LaC proteins. Bars show the 
mean SEM of duplicate optical density values (n=7 patients with primary SS).     
Fig. 2.  Representative 2-DE gels of affinity-purified anti-LaA IgG from patient 
SS107. (a) Under reduced conditions the heavy chain species running at ~55 kDa 
(gel plug 1) identifies as IGHV3-43 and IGHV3-30, and the light chain species 
running at ~25 kDa as IGKV3-15 (gel plugs 2,3) and IGKV3-20 (gel plugs 4,5). (b) 
Under non-reduced conditions the biclonal intact IgG species running at ~150 kDa 
comprises IGHV3-30/IGKV3-15 (gel plug 1) and IGHV3-43/IGHV3-20 (gel plug 2) 
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heavy and light chain pairings.  
 
Fig. 3.  Variable (V)-region peptide heat map of compiled de novo sequencing data 
from 7 patients with primary SS showing public (shared) mutations. (a) Heavy 
chain V-region sequences align with germline HV3-43 and HV3-30 (IMGT 
database). (b) Light chain V-region sequences align with germline KV3-20 and 
KV3-15. (c) Light chain J-regions align with KJ2 and KJ4 germline sequence and 
heavy chain J-regions aligned with HJ2. Due to a lack of overlapping peptides from 
the CDR3 region into the J-regions, the exact pairing of V- and J- regions could not 
be determined. Common mutations divergent from the germline sequence are 
depicted in text and colour coded according to the frequency of the mutation 
detected in the primary SS patient cohort analysed. Dots indicate amino acids 
matching to the germline sequence. CDR regions are boxed.  
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Table 1.  Characteristics of patients with primary Sjögren’s Syndrome  
 
Patient Age/Sex Duration of 
symptoms (years) 
Autoantibodies (OD)* Total IgG† 
(mg/mL) 
RF† 
(IU/mL) 
Ro52 Ro60 LaA 
SS127 68/F 14 2.4 2.4 2.1 15.3 697 
SS118 82/F 32 2.5 2.2 2.3 30.1 579 
SS102 54/F 15 2.4 2.4 1.7 23.8 154 
SS155 63/F 19 2.4 2.4 2.3 31.1 421 
SS179 80/F 31 2.1 2.1 2.5 50.4 1110 
SS137 23/F 5 1.7 1.4 2.5 16.1 540 
SS107 69/F 14 2.5 2.3 2.5 35.3 172 
Autoantibodies were measured by enzyme-linked immunosorbent assay, 
with optical density (OD) <0.2 considered normal; † total IgG and 
rheumatoid factor (RF) were measured by nephelometry. 
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Supplementary figure 
 
Fig. S1.   De novo sequencing data of anti-LaA IgGs purified from the sera of 7 
patients with primary SS, showing clonal restriction to (a) KV3-20; (b) KV3-15; (c) 
HV3-43; and (d) HV3-30 gene families. Public (shared) mutated V-region peptides 
collected from these sequences are tabulated by proteomic heat maps in Fig. 3. (e) 
Sequencing of J-regions reveals KJ2, KJ4 and HJ2. Dots indicate homology with 
germline sequence whilst mutations divergent from the germline indicated in text. 
Sequence in red text indicates peptides that could not be assigned specifically to 
either light chain due to a high degree of sequence homology between KV3-20 and 
KV3-15. CDRs are boxed.  
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Supplementary Table 
 
Table S1.  Comparison  of the relative affinities of anti-La IgG binding directed 
against immunodominant epitopes of La. 
 
 
Patient Affinity Index* 
LaA LaC La2/3 
SS127 1.59 1.38 2.96 
SS118 1.91 1.20 0.44 
SS102 1.99 > 4 1.12 
SS155 1.82 > 4 1.35 
SS179 2.14 3.88 1.95 
SS137 2.29 > 4 2.45 
SS107 1.73 1.80 0.75 
* Determined as the molar concentration of potassium thiocyanate (KSCN) 
required to elute 50% of effective antibody12. 
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Figure 2 
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Figure 3 
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